Top

Published in:

01-11-2014 | Original Communication

Concomitant accumulation of α-synuclein and TDP-43 in a patient with corticobasal degeneration

Authors: Satoshi Yamashita, Naomi Sakashita, Taro Yamashita, Nozomu Tawara, Masayoshi Tasaki, Kensuke Kawakami, Yoshihiro Komohara, Yukio Fujiwara, Masashi Kamikawa, Takenobu Nakagawa, Teruyuki Hirano, Yasushi Maeda, Masato Hasegawa, Motohiro Takeya, Yukio Ando

Published in: Journal of Neurology | Issue 11/2014

Abstract

Pathological changes in corticobasal degeneration (CBD) consist of abnormal deposition of the microtubule-associated protein tau. However, the simultaneous accumulation of different misfolded proteins in the brain can be observed in many neurodegenerative diseases with significantly longer disease durations. We encountered a patient with CBD who survived for an extremely long period (18 years) after the diagnosis. We performed an autopsy to elucidate the effect of the longer survival on the pathology of CBD. We observed abnormal aggregation of trans-activating response region DNA-binding protein of 43 kDa (TDP-43) and α-synuclein, as well as phosphorylated tau, in neurons of broader regions of the brain, beyond the amygdala and other limbic areas. We found that phosphorylated tau, α-synuclein, and TDP-43 partially co-existed in the same cellular aggregates. The triple pathologic changes might be related to the longer survival of the patient compared with the typical clinical course of patients with CBD. Further investigations are required to support the hypothesis that tauopathy, synucleinopathy, and TDP-43 proteinopathy might share common pathogenic mechanisms in terms of cross-seeding of the pathologic proteins.

Available only for authorised users

Rebeiz JJ, Kolodny EH, Richardson EP Jr (1968) Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18:20–33CrossRefPubMed

Boeve BF, Lang AE, Litvan I (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54(Suppl 5):S15–S19CrossRefPubMed

Dickson DW, Bergeron C, Chin SS et al (2002) Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935–946PubMed

Feany MB, Dickson DW (1995) Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 146:1388–1396PubMedCentralPubMed

Kouri N, Murray ME, Hassan A et al (2011) Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 134:3264–3275PubMedCentralCrossRefPubMed

Ling H, O’Sullivan SS, Holton JL et al (2010) Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133:2045–2057CrossRefPubMed

Aiba I (2012) Corticobasal syndrome: recent advances and future directions. Brain Nerve 64:462–473PubMed

Wenning GK, Litvan I, Jankovic J et al (1998) Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 64:184–189PubMedCentralCrossRefPubMed

Uryu K, Nakashima-Yasuda H, Forman MS et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67:555–564PubMedCentralCrossRefPubMed

10.

Arai T, Ikeda K, Akiyama H et al (2004) Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 55:72–79CrossRefPubMed

11.

Tsuji H, Arai T, Kametani F et al (2012) Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 135:3380–3391CrossRefPubMed

12.

Mackenzie IR, Neumann M, Baborie A et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113PubMedCentralCrossRefPubMed

13.

Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMed

14.

Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449–458CrossRefPubMed

15.

Clarimon J, Molina-Porcel L, Gomez-Isla T et al (2009) Early-onset familial Lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study. J Neuropathol Exp Neurol 68:73–82CrossRefPubMed

16.

Duda JE, Giasson BI, Mabon ME et al (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 104:7–11CrossRefPubMed

17.

Galloway PG, Grundke-Iqbal I, Iqbal K, Perry G (1988) Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles. J Neuropathol Exp Neurol 47:654–663CrossRefPubMed

18.

Giasson BI, Forman MS, Higuchi M et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636–640CrossRefPubMed

19.

Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389–397PubMed

20.

Terni B, Rey MJ, Boluda S et al (2007) Mutant ubiquitin and p62 immunoreactivity in cases of combined multiple system atrophy and Alzheimer’s disease. Acta Neuropathol 113:403–416CrossRefPubMed

21.

Wills J, Jones J, Haggerty T et al (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol 225:210–218PubMedCentralCrossRefPubMed

22.

Badiola N, de Oliveira RM, Herrera F et al (2011) Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One 6:e26609PubMedCentralCrossRefPubMed

23.

Iseki E, Marui W, Kosaka K, Ueda K (1999) Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett 265:9–12CrossRefPubMed

24.

Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378–384CrossRefPubMed

25.

Lippa CF, Fujiwara H, Mann DM et al (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365–1370PubMedCentralCrossRefPubMed

26.

Raghavan R, Khin-Nu C, Brown A et al (1993) Detection of Lewy bodies in Trisomy 21 (Down’s syndrome). Can J Neurol Sci 20:48–51PubMed

27.

Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to alpha-synuclein detect Lewy bodies in many down’s syndrome brains with Alzheimer’s disease. Ann Neurol 45:353–357CrossRefPubMed

28.

Judkins AR, Forman MS, Uryu K et al (2002) Co-occurrence of Parkinson’s disease with progressive supranuclear palsy. Acta Neuropathol 103:526–530CrossRefPubMed

29.

Forman MS, Schmidt ML, Kasturi S et al (2002) Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am J Pathol 160:1725–1731PubMedCentralCrossRefPubMed

30.

Wilhelmsen KC, Forman MS, Rosen HJ et al (2004) 17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions. Arch Neurol 61:398–406CrossRefPubMed

31.

Yancopoulou D, Xuereb JH, Crowther RA, Hodges JR, Spillantini MG (2005) Tau and alpha-synuclein inclusions in a case of familial frontotemporal dementia and progressive aphasia. J Neuropathol Exp Neurol 64:245–253PubMed

32.

Schmidt ML, Martin JA, Lee VM, Trojanowski JQ (1996) Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer’s disease and Lewy body disorders. Acta Neuropathol 91:475–481CrossRefPubMed

33.

Mooney T, Tampiyappa A, Robertson T et al (2011) Dual pathology of corticobasal degeneration and Parkinson’s disease in a patient with clinical features of progressive supranuclear palsy. Neurol India 59:887–890CrossRefPubMed

34.

Kouri N, Oshima K, Takahashi M et al (2013) Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. Acta Neuropathol 125:741–752PubMedCentralCrossRefPubMed

35.

Jellinger KA (2011) Interaction between alpha-synuclein and other proteins in neurodegenerative disorders. Sci World J 11:1893–1907CrossRef

36.

Jellinger KA (2012) Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med 16:1166–1183PubMedCentralCrossRefPubMed

Title: Concomitant accumulation of α-synuclein and TDP-43 in a patient with corticobasal degeneration
Authors: Satoshi Yamashita
Naomi Sakashita
Taro Yamashita
Nozomu Tawara
Masayoshi Tasaki
Kensuke Kawakami
Yoshihiro Komohara
Yukio Fujiwara
Masashi Kamikawa
Takenobu Nakagawa
Teruyuki Hirano
Yasushi Maeda
Masato Hasegawa
Motohiro Takeya
Yukio Ando
Publication date: 01-11-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 11/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-014-7491-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Concomitant accumulation of α-synuclein and TDP-43 in a patient with corticobasal degeneration

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2014

Accurate diagnosis of inflammatory neuropathies

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Late onset hereditary sensory and autonomic neuropathy with cognitive impairment associated with Y163X prion mutation

Ernest-Charles Lasègue (1816–1883)

Rare variant of unknown significance in POLG1 and diagnostic dilemma

Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort